Ortega-Paz L, Franchi F, Rollini F, Galli M, Been L, Ghanem G
JACC Basic Transl Sci. 2024; 9(7):865-876.
PMID: 39170956
PMC: 11334417.
DOI: 10.1016/j.jacbts.2024.03.003.
Vogel R, Delewi R, Badimon L, Angiolillo D, Vlachojannis G
Rev Cardiovasc Med. 2024; 23(9):297.
PMID: 39077705
PMC: 11262351.
DOI: 10.31083/j.rcm2309297.
Mostafa M, Eid M, Awad A, Takla A, Hassan A, Katamesh B
Am J Cardiovasc Drugs. 2023; 24(1):71-81.
PMID: 37995040
DOI: 10.1007/s40256-023-00616-2.
Kubica J, Adamski P, Dobrzycki S, Gajda R, Gasior M, Gierlotka M
Cardiol J. 2023; 31(1):133-146.
PMID: 37964649
PMC: 10919555.
DOI: 10.5603/cj.96076.
Konecki C, Holm M, Djerada Z
Clin Pharmacokinet. 2023; 62(6):905-920.
PMID: 37097605
DOI: 10.1007/s40262-023-01243-5.
Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study.
De Luca L, Calabro P, Chirillo F, Rolfo C, Menozzi A, Capranzano P
Clin Cardiol. 2022; 45(9):913-920.
PMID: 35733352
PMC: 9451664.
DOI: 10.1002/clc.23878.
P2Y Antagonists in Cardiovascular Disease-Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding.
Fernando H, McFadyen J, Wang X, Shaw J, Stub D, Peter K
Front Cardiovasc Med. 2022; 9:854813.
PMID: 35647068
PMC: 9133423.
DOI: 10.3389/fcvm.2022.854813.
Association between pre-hospital chest pain severity and myocardial injury in ST elevation myocardial infarction: A post-hoc analysis of the AVOID study.
Fernando H, Nehme Z, Peter K, Bernard S, Stephenson M, Bray J
Int J Cardiol Heart Vasc. 2021; 37:100899.
PMID: 34815999
PMC: 8591354.
DOI: 10.1016/j.ijcha.2021.100899.
Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy.
Bellis A, Di Gioia G, Mauro C, Mancusi C, Barbato E, Izzo R
J Clin Med. 2021; 10(13).
PMID: 34279451
PMC: 8268641.
DOI: 10.3390/jcm10132968.
Feasibility and safety of cangrelor in patients with suboptimal P2Y inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry.
Selvarajah A, Tavenier A, Bor W, Houben V, Rasoul S, Kaplan E
BMC Cardiovasc Disord. 2021; 21(1):292.
PMID: 34118880
PMC: 8199523.
DOI: 10.1186/s12872-021-02093-4.
Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.
Tavenier A, Hermanides R, Ottervanger J, Tolsma R, van Beurden A, Slingerland R
Eur Heart J Cardiovasc Pharmacother. 2020; 8(1):4-12.
PMID: 32730628
PMC: 8728016.
DOI: 10.1093/ehjcvp/pvaa095.
Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets.
Vootukuri S, Li J, Nedelman M, Thomas C, Jiang J, Babayeva M
J Clin Transl Sci. 2019; 3(2-3):65-74.
PMID: 31544007
PMC: 6753935.
DOI: 10.1017/cts.2019.382.
Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment.
Bergmeijer T, van Oevelen M, Janssen P, Godschalk T, Lichtveld R, Kelder J
TH Open. 2019; 2(4):e357-e368.
PMID: 31249961
PMC: 6524899.
DOI: 10.1055/s-0038-1673389.
Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials.
Bhogal S, Mukherjee D, Bagai J, Truong H, Panchal H, Murtaza G
Cardiovasc Hematol Disord Drug Targets. 2019; 20(1):3-15.
PMID: 31241442
PMC: 7360918.
DOI: 10.2174/1871529X19666190626124057.
A randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd....
Tavenier A, Hermanides R, Ottervanger J, Rasoul S, Slingerland R, Tolsma R
Neth Heart J. 2019; 27(4):185-190.
PMID: 30767166
PMC: 6439041.
DOI: 10.1007/s12471-019-1241-6.
The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI.
Pavlovic M, Apostolovic S, Stokanovic D, Lilic J, Konstantinovic S, Zvezdanovic J
Int J Clin Pharm. 2018; 40(6):1482-1489.
PMID: 30367373
DOI: 10.1007/s11096-018-0730-9.
Point of Care Tests VerifyNow P2Y12 and INNOVANCE PFA P2Y Compared to Light Transmittance Aggregometry After Fibrinolysis.
Roule V, Ardouin P, Repesse Y, Le Querrec A, Blanchart K, Lemaitre A
Clin Appl Thromb Hemost. 2018; 24(7):1109-1116.
PMID: 29719963
PMC: 6714754.
DOI: 10.1177/1076029618772354.
Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.
Adamski P, Sikora J, Laskowska E, Buszko K, Ostrowska M, Uminska J
PLoS One. 2017; 12(10):e0186013.
PMID: 29023473
PMC: 5638327.
DOI: 10.1371/journal.pone.0186013.
Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.
Adamski P, Ostrowska M, Sikora J, Obonska K, Buszko K, Krintus M
BMJ Open. 2017; 7(4):e013218.
PMID: 28446521
PMC: 5541360.
DOI: 10.1136/bmjopen-2016-013218.
An Updated Protocol for Evaluating Chest Pain and Managing Acute Coronary Syndromes.
Kelly C, Kirtane A, Stant J, Stone G, Minutello R, Wong S
Crit Pathw Cardiol. 2017; 16(1):7-14.
PMID: 28195937
PMC: 5462108.
DOI: 10.1097/HPC.0000000000000098.
